Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab subcutaneous induction therapy in moderately to severely active ulcerative colitis (Phase 2/3, dose-ranging, placebo-controlled)
2006-003398-28Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Golimumab induction arm with Placebo arm (2 arms). Primary endpoint: Clinical remission induction (dose-ranging part). Started Jul 2007; status: completed.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-003398-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003398-28.